ONCYClinical Trials•prnewswire•September 2, 2025 at 01:10 PM

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Sentiment:Positive (70)

Summary

(NASDAQ:ONCY) Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with multiple treatments Updated clinical data now account for over 300 gastrointestinal cancer patients, including patients from the GOBLET study, demonstrating...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 2, 2025 by prnewswire